Ultralife (ULBI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for July 16, 2025, at the Atlanta Airport Marriott Gateway, with voting available online or in person.
Shareholders are encouraged to review proxy materials and annual report before voting.
Voting matters and shareholder proposals
Election of five directors: Michael E. Manna, Janie Goddard, Thomas L. Saeli, Robert W. Shaw II, and Bradford T. Whitmore.
Ratification of Freed Maxick P.C. as independent registered public accounting firm for fiscal year ending December 31, 2025.
Proxies may vote on other business as may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting for all director nominees.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Ultralife
- Q4 revenue up 10.6% year-over-year; impairment led to net loss, but backlog and new products support 2026 growth.ULBI
Q4 202510 Mar 2026 - Q2 revenue up 13% to $48.6M, but margins and net income declined; outlook for H2 is positive.ULBI
Q2 20253 Feb 2026 - Record segment sales, margin gains, and major debt reduction highlight Q2 2024.ULBI
Q2 20243 Feb 2026 - Q3 revenue and profit declined, but debt reduction and a $50M acquisition set up future growth.ULBI
Q3 202415 Jan 2026 - Q4 revenue was $43.9M, with Electrochem acquisition and strong backlog driving 2025 growth.ULBI
Q4 202424 Dec 2025 - Director elections, auditor ratification, and governance updates highlight the 2025 proxy.ULBI
Proxy Filing1 Dec 2025 - Q1 2025 revenue up 21% to $50.7M, but net income and margins declined on higher costs.ULBI
Q1 202526 Nov 2025 - Q3 2025 revenue up 21.5% to $43.4M, but net loss of $1.22M on lower margins and one-time costs.ULBI
Q3 202519 Nov 2025